ScripGilead Sciences’ Yeytuo (lenacapavir) and Eli Lilly’s Kisunla (donanemab) are among the drugs that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral
Pink SheetThe European Medicines Agency has recommended that Gilead Sciences’ Yeytuo (lenacapavir), for preventing HIV, and 13 other new drugs should be granted pan-EU marketing authorization, but it has advise
Pink SheetA public airing of the questions about Sarepta Therapeutics ' remaining gene therapies and their vector could be an option for the US Food and Drug Administration as it works to sort out ongoing safe